“Apart from fighting the formation of amyloid-beta plaques or neurofibrillary tangles, acting on the neuroinflammation mechanisms could be a suitable therapeutic strategy to stop the progression of such a complex disease like Alzheimer’s,” said Professor Carmen Escolano, lead researcher of the study.
‘LSL60101 modifies disease markers related to oxidative stress and neuroinflammation. It also showed higher efficacy when combined with the drug donepezil.’
Animal studies confirmed LSL60101 efficacy
The team used mice models to study the interactions between LSL60101 and imidazoline I2 receptors. They found that the compound was highly efficient in creating changes in the markers of neurodegenerative disorders related to oxidative stress and neuroinflammation.
It parallelly reduced the number of amyloid-beta plaques and phosphorylation of the tau protein, which are important in disseminating the diseases.
How about the ‘LSL60101-Donepezil’ combination?
Further, the researchers tested the efficacy of the ‘LSL60101-Donepezil’ combination. Donepezil is a medication widely used in the treatment of Alzheimer’s disease.
They highlighted: “The results show that the LS60101-donepezil combined therapy is more efficient in some biomarkers of the disease. Therefore, it is possible that, with the combination of the suitable dose, we could reach an additive or even synergic effect.”
It is important to note that more than 6 million Americans might develop dementia due to Alzheimer’s disease on an average, according to field experts. The findings of this new study provide new insights into the treatment of neurodegenerative disorders.
Source: Medindia
